Arovella Therapeutics Ltd
ASX:ALA
Net Margin
Arovella Therapeutics Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Arovella Therapeutics Ltd
ASX:ALA
|
106.5m AUD |
-1 416%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
729.1B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.2B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.3B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.6B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
201.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.6B USD |
13%
|
Arovella Therapeutics Ltd
Glance View
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Arovella Therapeutics Ltd's most recent financial statements, the company has Net Margin of -1 416.4%.
You don't have any saved screeners yet